Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

You may be eligible if

• Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria (Trautinger et al, Eur J Cancer, 2017)
• Age ≥18 years
• Have failed at least one previous line of systemic therapy
• Have received mogamulizumab in real life setting after the approval and reimbursement of the drug from the National Health System in December 2020
• Have received first dose of mogamulizumab between 01/01/2021 and 31/01/2023
• Have received mogamulizumab at the standard approved dose (1.0 mg/kg intravenously on days 1, 8, 15 and 22 of the first cycle and on days 1 and 15 of subsequent cycles)
• Availability of complete medical records.